Skip to content
10-Q

Quarterly Report

XERIS BIOPHARMA HOLDINGS, INC. XERS

0001867096-26-000030

← back to feed
Filed
May 7, 2026 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2026 · Apr 30, 2026 172.64M sh
Shares Diluted Q1 2026 · Mar 31, 2026 177.63M sh
Shares Diluted Q1 2026 · Mar 31, 2025 152.45M sh
Operating Cash Flow Q1 2026 · Mar 31, 2026 $9.87M
Operating Cash Flow Q1 2026 · Mar 31, 2025 −$10.03M
Long Term Debt Q1 2026 · Mar 31, 2026 $221.22M
Long Term Debt Q1 2026 · Dec 31, 2025 $220.34M
Cash And Equivalents Q1 2026 · Mar 31, 2026 $111.75M
Cash And Equivalents Q1 2026 · Dec 31, 2025 $111.04M
Cash And Equivalents Q1 2026 · Mar 31, 2025 $58.44M
Stockholders Equity Q1 2026 · Mar 31, 2026 $13.01M
Stockholders Equity Q1 2026 · Dec 31, 2025 $13.69M
Stockholders Equity Q1 2026 · Mar 31, 2025 −$35.13M
Stockholders Equity Q1 2026 · Dec 31, 2024 −$29.62M
Current Liabilities Q1 2026 · Mar 31, 2026 $118.59M
Current Liabilities Q1 2026 · Dec 31, 2025 $109.57M
Total Liabilities Q1 2026 · Mar 31, 2026 $379M
Total Liabilities Q1 2026 · Dec 31, 2025 $369.84M
Current Assets Q1 2026 · Mar 31, 2026 $251.68M
Current Assets Q1 2026 · Dec 31, 2025 $240.31M
Total Assets Q1 2026 · Mar 31, 2026 $392.01M
Total Assets Q1 2026 · Dec 31, 2025 $383.53M
Eps Diluted Q1 2026 · Mar 31, 2026 $0.01
Eps Diluted Q1 2026 · Mar 31, 2025 −$0.06
Eps Basic Q1 2026 · Mar 31, 2026 $0.01
Eps Basic Q1 2026 · Mar 31, 2025 −$0.06
Sga Expense Q1 2026 · Mar 31, 2026 $53.14M
Sga Expense Q1 2026 · Mar 31, 2025 $44.02M
Rd Expense Q1 2026 · Mar 31, 2026 $8.78M
Rd Expense Q1 2026 · Mar 31, 2025 $7.75M
Net Income Q1 2026 · Mar 31, 2026 $2.23M
Net Income Q1 2026 · Mar 31, 2025 −$9.22M
Operating Income Q1 2026 · Mar 31, 2026 $7.92M
Operating Income Q1 2026 · Mar 31, 2025 −$3.09M
Revenue Q1 2026 · Mar 31, 2026 $83.13M
Revenue Q1 2026 · Mar 31, 2025 $60.12M